Phoshorylation of Estrogen Receptor Alpha Serine 282 as a Marker for Endocrine Therapies in Breast Cancer

摘要

The present invention provides diagnostic methods and markers based on the phosphorylation state of certain amino acid residues of estrogen receptorα. The invention relates to the phosphorylation of specific estrogen receptor alpha residues as a marker for susceptibility to chemotherapy. The invention specifically discloses the phosphorylation of serine 282 of the ER-alpha, as a diagnostic marker for breast cancer cells which are more responsive to hormone therapy than cells without the said phosphorylation.